Affiliation:
1. Department of Musculoskeletal Ageing and Science, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool L7 8TX, UK
2. Department of Orthopedics, Police General Hospital, Bangkok 10330, Thailand
3. South London and Maudsley NHS Foundation Trust, London SE5 8AZ, UK
Abstract
Sarcopenia, a progressive disease characterized by a decline in muscle strength, quality, and mass, affects aging population worldwide, leading to increased morbidity and mortality. Besides resistance exercise, various nutritional strategies, including omega-3 polyunsaturated fatty acid (n-3 PUFA) supplementation, have been sought to prevent this condition. This narrative review summarizes the current evidence on the effect and mechanism of n-3 PUFA on musculoskeletal health. Despite conflicting evidence, n-3 PUFA is suggested to benefit muscle mass and volume, with more evident effects with higher supplementation dose (>2 g/day). n-3 PUFA supplementation likely improves handgrip and quadriceps strength in the elderly. Improved muscle functions, measured by walking speed and time-up-to-go test, are also observed, especially with longer duration of supplementation (>6 months), although the changes are small and unlikely to be clinically meaningful. Lastly, n-3 PUFA supplementation may positively affect muscle protein synthesis response to anabolic stimuli, alleviating age-related anabolic resistance. Proposed mechanisms by which n-3 PUFA supplementation improves muscle health include 1. anti-inflammatory properties, 2. augmented expression of mechanistic target of rapamycin complex 1 (mTORC1) pathway, 3. decreased intracellular protein breakdown, 4. improved mitochondrial biogenesis and function, 5. enhanced amino acid transport, and 6. modulation of neuromuscular junction activity. In conclusion, n-3 PUFAs likely improve musculoskeletal health related to sarcopenia, with suggestive effect on muscle mass, strength, physical performance, and muscle protein synthesis. However, the interpretation of the findings is limited by the small number of participants, heterogeneity of supplementation regimens, and different measuring protocols.
Subject
Drug Discovery,Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Pharmaceutical Science
Reference139 articles.
1. Sarcopenia: Revised European consensus on definition and diagnosis;Bahat;Age Ageing,2019
2. Clinical definition of sarcopenia;Santilli;Clin. Cases Miner. Bone Metab.,2014
3. Sarcopenia as a risk factor for falls in elderly individuals: Results from the ilSIRENTE study;Landi;Clin. Nutr.,2012
4. Sarcopenia Definitions as Predictors of Fracture Risk Independent of FRAX(®), Falls, and BMD in the Osteoporotic Fractures in Men (MrOS) Study: A Meta-Analysis;Harvey;J. Bone Miner. Res.,2021
5. Nishikawa, H., Asai, A., Fukunishi, S., Nishiguchi, S., and Higuchi, K. (2021). Metabolic Syndrome and Sarcopenia. Nutrients, 13.
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献